API
< Back to all clusters
[HEALTH] · United States · 2 sources

started · updated

FDA approves Ameluz topical gel for superficial basal cell carcinoma

The FDA has approved Ameluz, a 10% topical aminolevulinic acid hydrochloride gel used in combination with photodynamic therapy (PDT), for the treatment of superficial basal cell carcinoma. This marks the first and only photodynamic therapy approved by the FDA specifically for treating a type of skin cancer in the United States.

The approval follows a Phase 3 clinical trial involving 187 adults across 21 U.S. centers. The study demonstrated that 66% of patients receiving the topical gel and photodynamic therapy achieved a response, compared to 5% in the placebo group. Additionally, 83% of treated patients achieved complete clinical clearance of all target lesions, whereas only 21% achieved this in the placebo arm.

Ameluz provides a non-surgical, in-office option for patients with the superficial subtype of basal cell carcinoma, which accounts for an estimated 15% to 20% of the approximately 3.6 million annual cases in the U.S. The treatment involves applying the gel to the lesion for approximately three hours before exposing the area to red light to trigger a reaction that damages abnormal cells. Common side effects reported were application-site reactions.

Entities

Ameluz · Biofrontera · FDA